NCT00546520已完成3 期
A 3-period Double-blind, Cross-over Study on the Onset of Action of Inhaled Ciclesonide (7 Days of 400 mcg Sid Versus 800 mcg Bid Versus Placebo) on Airway Responsiveness to Adenosine Monophosphate (AMP), Sputum Eosinophiles and Exhaled Breath Nitric Oxide (NO) in Patients With Asthma
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 21
- 试验地点
- 1
- 主要终点
- PC20FEV1 (AMP)
研究概览
简要总结
Ciclesonide is a novel inhaled corticosteroid for the treatment of asthma. In this study the effect of ciclesonide on airway hyperresponsiveness (AHR), exhaled nitric oxide (NO), and induced sputum inflammatory biomarkers will be evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Main inclusion criteria:
- •Out-patients
- •Written informed consent
- •History of atopic disease
- •History of perennial bronchial asthma for at least 6 months as defined by ATS criteria
- •Current use of only inhaled short acting beta-2-agonist as required (for at least 4 weeks prior to baseline period B0)
- •Stable asthma, i.e. no exacerbation or relevant respiratory tract infection within 2 months prior to study start
- •FEV1 ≥ 70% predicted
- •Hyperreactivity to AMP (PC20FEV1 < 25 mg/ml)
- •Good health with the exception of asthma
- •Non-smokers as well as ex-smokers with either = 10 pack-years or more than 6 months of smoking abstinence
排除标准
- •Concomitant severe diseases or diseases which are contraindications for the use of inhaled steroids (e.g. lung tuberculosis)
- •Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation
- •Use of systemic steroids 4 weeks (injectable depot steroids 6 weeks) before entry into the baseline period, or more than 3 times during the last 6 months
- •Pregnancy or intention to become pregnant during the course of the study, breast feeding, lack of safe contraception in heterosexually active female patients of child-bearing potential, or postmenopausal for less than one year
- •COPD (i.e. chronic bronchitis or emphysema) and/or other relevant lung diseases
- •Known or suspected hypersensitivity to inhaled steroids or to the other excipients of the metered dose inhalers
- •Immunotherapy within one month prior to B0 and/or during the entire study duration
结局指标
主要结局
PC20FEV1 (AMP)
次要结局
- Baseline FEV1 from spirometry, exhaled NO, eosinophils, basophils, and mast cells determined from induced sputum; Safety variables: Physical examination, vital signs, ECG, laboratory work-up, and adverse events
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Dose Response Study of Inhaled Ciclesonide (Glucocorticosteroid) to Patients With Persistent AsthmaAsthmaNCT00174746Sanofi1,145
已完成
不适用
Efficacy of Ciclesonide During the Cold Season in Patients Older Than 12 Years With Persistent AsthmaAsthmaNCT00608218AstraZeneca2,100
已完成
4 期
Ciclesonide for the Treatment of Airway HyperresponsivenessAsthmaNCT00826969AstraZeneca64
已完成
2 期
A multicenter, open-label, randomized controlled phase II study to evaluate the efficacy and safety of inhaled ciclesonide for asymptomatic and mild patients with COVID-19D000073640COVID-19JPRN-jRCTs031190269Sugiyama Haruhito90
已完成
4 期
Dose Response Effects of Inhaled Fluticasone on Airway Effects of Hypertonic-saline in AsthmaAsthmaNCT00606242University of California, San Francisco44